CIK: 0001400240
Total reported value
$1.2B
Reporting period: 2026-03-31 · Number of holdings: 7
Flagship Pioneering, LLC disclosed 7 holdings in its latest 13F filing for the period ending 2026-03-31, with total reported value of $1.2B and a quarterly turnover rate of 124.8%.
Browse other institutions with $1B to $10B AUMBrowse other institutions starting with "F"
Flagship Pioneering, LLC's disclosed holdings carry a Herfindahl concentration index of 0.503 — mathematically equivalent to about 2 equally-sized positions, well below its 7 actual disclosed holdings. That gap points to a strategy built around a small core of high-conviction bets rather than broad diversification.
Position sizes vary widely across the portfolio (a coefficient of variation of 1.38), with a handful of outsized bets alongside many smaller positions.
Recent activity leans toward initiating meaningfully larger new positions than it adds to existing ones (a 67.4 percentage-point tilt) — a pattern consistent with a more contrarian, new-idea-driven approach.
Sector classification currently covers about 20% of this portfolio's disclosed value; the remainder includes holdings (e.g. unmapped tickers, options, or other security types) not yet covered by our sector mapping.
Trim SANA
0.0% -$29.8M
Trim MRNA
0.0% $98.7M
Trim FHTX
0.0% -$7.9M
Trim MCRB
0.0% -$7.0M
New buy GENB
Showing top 5 holdings (of 7 total)
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | GENB | Generate Biomedicines INC | Stock-Other | 67.44% | +67.44% | NEW | |
| 2 | MRNA | Moderna INC | Stock-Healthcare | 20.26% | -21.90% | — | |
| 3 | SANA | Sana Biotechnology INC | Stock-Other | 6.20% | -25.20% | — | |
| 4 | FHTX | Foghorn Therapeutics INC | Stock-Other | 5.22% | -15.90% | — | |
| 5 | MCRB | Seres Therapeutics INC | Stock-Other | 0.88% | -4.44% | — |
Performance for Q3 2026
+2.6%
Performance Last 4 Quarters
+2.6%
Based on 2 months of available history
Based on 74% of reported portfolio value with available pricing
| Period | Holdings | Total value | Stability | Top holdings |
|---|---|---|---|---|
| 2026-03-31 | 7 | $1.2B | 100 | |
| 2025-12-31 | 6 | $324.0M | 13 | |
| 2025-09-30 | 8 | $292.6M | 40 | |
| 2025-06-30 | 8 | $268.5M | 0 | |
| 2025-03-31 | 8 | $235.8M | 100 | |
| 2024-12-31 | 10 | $334.2M | 0 | |
| 2024-09-30 | 12 | $591.9M | 0 | |
| 2024-06-30 | 12 | $843.4M | 0 | |
| 2024-03-31 | 13 | $1.5B | 0 | |
| 2023-12-31 | 13 | $1.3B | 0 | |
| 2023-09-30 | 18 | $1.4B | 0 | |
| 2023-06-30 | 20 | $2.2B | 0 | |
| 2023-03-31 | 22 | $2.6B | 0 | |
| 2022-12-31 | 25 | $3.1B | 0 | |
| 2022-09-30 | 35 | $2.4B | 0 | |
| 2022-06-30 | 33 | $2.7B | 0 | |
| 2022-03-31 | 38 | $4.3B | 0 | |
| 2021-12-31 | 38 | $6.5B | 0 | |
| 2021-09-30 | 38 | $9.5B | 0 | |
| 2021-06-30 | 33 | $7.8B | 89 | |
| 2021-03-31 | 33 | $6.2B | 51 | |
| 2020-12-31 | 30 | $5.5B | 54 | |
| 2020-09-30 | 17 | $3.6B | 29 | |
| 2020-06-30 | 17 | $3.4B | 47 | |
| 2020-03-31 | 17 | $2.1B | 39 | |
| 2019-12-31 | 19 | $1.8B | 17 | |
| 2019-09-30 | 20 | $1.8B | 32 | |
| 2019-06-30 | 20 | $2.3B | 28 | |
| 2019-03-31 | 15 | $2.6B | 33 | |
| 2018-12-31 | 12 | $2.0B | 73 | |
| 2018-09-30 | 10 | $1.5B | 100 | |
| 2018-06-30 | 7 | $522.1M | 66 | |
| 2018-03-31 | 4 | $344.9M | 39 | |
| 2017-12-31 | 5 | $394.3M | 85 | |
| 2017-09-30 | 5 | $299.0M | 37 | |
| 2017-06-30 | 5 | $283.6M | 29 | |
| 2017-03-31 | 9 | $376.3M | 22 | |
| 2016-12-31 | 9 | $307.3M | 23 | |
| 2016-09-30 | 9 | $366.0M | 0 |
Flagship Pioneering, LLC's most significant position changes for 2026-03-31: New buy: Generate Biomedicines INC (GENB).
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | MCRB | Seres Therapeutics INC | -4.4% | — | Unchanged |
| 2 | FHTX | Foghorn Therapeutics INC | -15.9% | — | Unchanged |
| 3 | MRNA | Moderna INC | -21.9% | — | Unchanged |
| 4 | SANA | Sana Biotechnology INC | -25.2% | — | Unchanged |
| 5 | GENB | Generate Biomedicines INC | — | NEW | New buy |
| Period | Filed | Type | EDGAR |
|---|---|---|---|
| 2026-03-31 | 2026-05-15 | 13F-HR | View on EDGAR |
| 2025-12-31 | 2026-02-17 | 13F-HR | View on EDGAR |
| 2025-09-30 | 2025-11-14 | 13F-HR | View on EDGAR |
| 2025-06-30 | 2025-08-14 | 13F-HR | View on EDGAR |
| 2025-03-31 | 2025-05-15 | 13F-HR | View on EDGAR |
| 2024-12-31 | 2025-02-14 | 13F-HR | View on EDGAR |
| 2024-09-30 | 2024-11-14 | 13F-HR | View on EDGAR |
| 2024-06-30 | 2024-08-14 | 13F-HR | View on EDGAR |
| 2024-03-31 | 2024-05-15 | 13F-HR | View on EDGAR |
| 2023-12-31 | 2024-02-14 | 13F-HR | View on EDGAR |
| 2023-09-30 | 2023-11-14 | 13F-HR | View on EDGAR |
| 2023-06-30 | 2023-08-14 | 13F-HR | View on EDGAR |
| 2023-03-31 | 2023-05-15 | 13F-HR | View on EDGAR |
| 2022-12-31 | 2023-02-14 | 13F-HR | View on EDGAR |
| 2022-09-30 | 2022-11-14 | 13F-HR | View on EDGAR |
| 2022-06-30 | 2022-08-15 | 13F-HR | View on EDGAR |
| 2022-03-31 | 2022-05-16 | 13F-HR | View on EDGAR |
| 2021-12-31 | 2022-02-14 | 13F-HR | View on EDGAR |
| 2021-09-30 | 2021-11-15 | 13F-HR | View on EDGAR |
| 2021-06-30 | 2021-08-16 | 13F-HR | View on EDGAR |
| 2021-03-31 | 2021-05-17 | 13F-HR | View on EDGAR |
| 2020-12-31 | 2021-02-16 | 13F-HR | View on EDGAR |
| 2020-09-30 | 2020-11-16 | 13F-HR | View on EDGAR |
| 2020-06-30 | 2020-08-13 | 13F-HR | View on EDGAR |
| 2020-03-31 | 2020-05-14 | 13F-HR | View on EDGAR |
| 2019-12-31 | 2020-02-13 | 13F-HR | View on EDGAR |
| 2019-09-30 | 2019-11-14 | 13F-HR | View on EDGAR |
| 2019-06-30 | 2019-08-13 | 13F-HR | View on EDGAR |
| 2019-03-31 | 2019-05-14 | 13F-HR | View on EDGAR |
| 2018-12-31 | 2019-02-13 | 13F-HR | View on EDGAR |
| 2018-09-30 | 2018-11-13 | 13F-HR | View on EDGAR |
| 2018-06-30 | 2018-08-07 | 13F-HR | View on EDGAR |
| 2018-03-31 | 2018-05-15 | 13F-HR | View on EDGAR |
| 2017-12-31 | 2018-02-14 | 13F-HR | View on EDGAR |
| 2017-09-30 | 2017-11-03 | 13F-HR | View on EDGAR |
| 2017-06-30 | 2017-08-02 | 13F-HR | View on EDGAR |
| 2017-03-31 | 2017-05-10 | 13F-HR | View on EDGAR |
| 2016-12-31 | 2017-02-13 | 13F-HR | View on EDGAR |
| 2016-09-30 | 2016-11-14 | 13F-HR | View on EDGAR |
Institutions with a similar AUM
CIK 0001740837
Total reported value
$1.2B
49 stks
2026-03-31
AUM within 0.0% of this institution
CIK 0001619899
Total reported value
$1.2B
155 stks
2026-03-31
AUM within 0.1% of this institution
CIK 0001556245
Total reported value
$1.2B
96 stks
2026-03-31
AUM within 0.1% of this institution
Institutions with overlapping top holdings
CIK 0000310158
Total reported value
$349.4M
14 stks
2026-03-31
1 of the top 5 holdings overlap, including Moderna INC
CIK 0001201001
Total reported value
$100.9M
5 stks
2026-03-31
1 of the top 5 holdings overlap, including Generate Biomedicines INC
CIK 0001223025
Total reported value
$426.7M
242 stks
2022-12-31
Stale — no recent filing
1 of the top 5 holdings overlap, including Moderna INC